fda ban bpc 157 BREAKING #PEPTIDE NEWS: BPC-157 has officially passed the vote needed for recommendation to the bulks list. #bpc157 atta boy @gabrielalizaidy FDA panel backs easier access

In a trial of patients with T2DM and BMI 27 kg/m2 or more receiving semaglutide injection for weight management, retinal disorders were reported by 6.9% of patients treated with semaglutide 2.4 mg/week, 6.2% of patients treated with semaglutide 1 mg/week, and 4.2% of patients treated with placebo

Tesamorelin, on the other hand, may contribute to more systemic changes in metabolic function

Among the peptides in common clinical use, sermorelin has a more stable regulatory history than many newer compounds

JCI Insight 2 , e90019 (2017)

Each batch undergoes rigorous third-party lab testing to verify purity and molecular integrity